Sanofi SA (SASY.PA)

SASY.PA on Paris Stock Exchange

68.94EUR
9 Feb 2016
Change (% chg)

€-0.97 (-1.39%)
Prev Close
€69.91
Open
€71.31
Day's High
€71.50
Day's Low
€67.83
Volume
5,709,276
Avg. Vol
3,288,801
52-wk High
€101.10
52-wk Low
€67.83

SASY.PA

Chart for SASY.PA

About

Sanofi SA is a healthcare company focused on patient needs and engaged in the research, development, manufacture and marketing of healthcare products. The Company is organized around three principal activities: Pharmaceuticals, Human Vaccines via Sanofi Pasteur, and Animal Health via Merial. The Company invests in emerging... (more)

Overall

Beta: 0.79
Market Cap(Mil.): €91,282.02
Shares Outstanding(Mil.): 1,305.71
Dividend: 2.85
Yield (%): 4.08

Financials

  SASY.PA Industry Sector
P/E (TTM): 17.59 31.84 38.49
EPS (TTM): 3.97 -- --
ROI: -- 15.02 14.34
ROE: -- 15.68 15.18
Search Stocks

Regeneron sees gradual adoption of cholesterol drug Praluent

Regeneron Pharmaceuticals Inc reported lower-than-expected quarterly sales for its new cholesterol drug and reiterated expectations of a "gradual uptake" for the treatment, which has been tipped to be its next blockbuster.

09 Feb 2016

UPDATE 3-Regeneron sees gradual adoption of cholesterol drug Praluent

* Shares down 5.3 pct at $369.77 (Adds details from conference call, analyst comment)

09 Feb 2016

Sanofi pledges stable 2016 earnings

PARIS Sanofi said it expected stable earnings per share this year after reporting lower fourth-quarter income on Tuesday, hurt by declining sales of diabetes and cancer treatments and other prescription drugs.

09 Feb 2016

Sanofi pledges stable 2016 earnings

PARIS Sanofi said it expected stable earnings per share this year after reporting lower fourth-quarter income on Tuesday, hurt by declining sales of diabetes and cancer treatments and other prescription drugs.

09 Feb 2016

UPDATE 2-Sanofi pledges stable 2016 earnings

* Proposes 2.93 euro dividend (Adds details, comment, share price)

09 Feb 2016

BRIEF-Zealand Pharma Q4 lixisenatide (Lyxumia) royalty rev up 31 pct at DKK 8.1 mln

* Q4 royalty revenue from Sanofi's sales of lixisenatide (Lyxumia) outside US up at 8.1 million Danish crowns / 1.1 million euros ($1.23 million), up 15 pct over Q3, up 31 pct over Q4 2014

09 Feb 2016

Sanofi pledges stable 2016 earnings despite headwinds

PARIS, Feb 9 Sanofi reported lower fourth-quarter earnings on Tuesday, hurt by declining sales in key divisions such as diabetes, oncology and prescription drugs, but said it expected 2016 earnings per share to be stable.

09 Feb 2016

EU mergers and takeovers (Feb 8)

BRUSSELS, Feb 8 The following are mergers under review by the European Commission and a brief guide to the EU merger process:

08 Feb 2016

EU mergers and takeovers (Feb 5)

BRUSSELS, Feb 5 The following are mergers under review by the European Commission and a brief guide to the EU merger process:

05 Feb 2016

EU mergers and takeovers (Feb 4)

BRUSSELS, Feb 4 The following are mergers under review by the European Commission and a brief guide to the EU merger process:

04 Feb 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Thomson Reuters ONE
£0.00
Provider : Thomson Reuters ONE
£0.00
Provider : Finlabo SIM Spa
£7.00
Provider : S&P Capital IQ – STARS Reports
£82.00
Provider : Reuters Investment Profile
£10.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks